Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D0V2QU
|
|||
Former ID |
DNCL002074
|
|||
Drug Name |
Anti-CD22/CD19 mab-toxin conjugate
|
|||
Drug Type |
Monoclonal antibody
|
|||
Indication | Acute lymphoblastic leukaemia [ICD-11: 2A85; ICD-10: C85.1, C88.7] | Investigative | [1] | |
Company |
Abiogen Pharma
|
Target and Pathway | Top | |||
---|---|---|---|---|
Target(s) | B-cell receptor CD22 (CD22) | Target Info | Modulator | [1] |
B-lymphocyte surface antigen B4 (CD19) | Target Info | Modulator | [1] | |
KEGG Pathway | PI3K-Akt signaling pathway | |||
Hematopoietic cell lineage | ||||
B cell receptor signaling pathway | ||||
Epstein-Barr virus infection | ||||
Primary immunodeficiency | ||||
Cell adhesion molecules (CAMs) | ||||
NetPath Pathway | IL-7 Signaling Pathway | |||
Panther Pathway | B cell activation | |||
Pathway Interaction Database | BCR signaling pathway | |||
Reactome | PIP3 activates AKT signaling | |||
Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell | ||||
Constitutive Signaling by Aberrant PI3K in Cancer | ||||
Antigen activates B Cell Receptor (BCR) leading to generation of second messengers | ||||
WikiPathways | Human Complement System | |||
Signaling by the B Cell Receptor (BCR) | ||||
PIP3 activates AKT signaling | ||||
B Cell Receptor Signaling Pathway | ||||
Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell |
References | Top | |||
---|---|---|---|---|
REF 1 | Immunotoxins against CD19 and CD22 are effective in killing precursor-B acute lymphoblastic leukemia cells in vitro. Leukemia. 2000 May;14(5):853-8. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.